High glucose associated YTHDC1 lactaylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy
Ontology highlight
ABSTRACT: High glucose associated YTHDC1 lactaylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy
PROVIDER: PRJNA1234198 | ENA |
REPOSITORIES: ENA
ACCESS DATA